CClinicalTrials.gg
CompletedNCT01878019Updated Dec 9, 2019

Brain Response to Pain Control in People With Chronic Pain

An observational study in Pain, sponsored by National Center for Complementary and Integrative Health (NCCIH). Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-09.

Sponsored by National Center for Complementary and Integrative Health (NCCIH) · Observational

Study type
Observational
Time perspective
Prospective
Enrollment
92
Ages
18 Years and older
Sex
All
01

Study summary

Background:

  • Researchers want to look at how the brain responds to painful stimulations. They also want to see if these responses are different in people with and without chronic pain. To test the brain s response, they will use a chemical called naloxone. Naloxone is used to treat overdoses of painkilling drugs like morphine. It may be able to block the effect of a pain-relieving cream. Researchers will apply a pain-relieving cream to a person s lower leg and look at the results of sensitivity tests with either naloxone or a placebo. This study will compare the results from people with chronic pain (like fibromyalgia) to those of people without chronic pain.

Objectives:

  • To look at the brain s response to pain in people with and without chronic pain.

Eligibility:

  • Individuals at least 18 years of age who have fibromyalgia.
  • Healthy volunteers at least 18 years of age.

Design:

  • This study will involve a screening visit and two testing visits. The testing visits will be about a week apart.
  • Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. After the screening participants will be administered several questionnaires about their personality, and their thoughts and feelings.
  • At the first visit, participants will try out the magnetic resonance imaging (MRI) scan before using it at the next visit. They will then have the painkilling cream applied on one part of their lower leg and a normal moisturizing cream on the other part of their lower leg. They will have heat pulses on these skin areas and rate the pain.
  • At the second visit, participants will have tests in the MRI scanner. The heat pulse tests will be repeated after an infusion of either naloxone or a placebo.
Read the detailed description

Different pain reducing drugs work in different ways to reduce pain. Many drugs, including morphine and codeine, reduce pain by binding to opiate receptors in the brain. Another chemical, naloxone, can block the effect of these drugs. In this study, we are looking at brain responses to a pain-relieving cream and whether naloxone blocks the effect of the cream. We will compare the results of people with chronic pain (fibromyalgia) to those of people without chronic pain.

Design:

The study compares MRI response to painful stimulation between people with fibromyalgia and healthy volunteers under two conditions: 1) naloxone, 2) placebo.

Outcome measures: Pain ratings and pain-related MRI responses are compared between people with fibromyalgia and healthy volunteers

02

Conditions studied

  • Pain

Browse trials for

Keywords

  • Pain
  • Placebo
  • Opiate Antagonist
03

In context

Chronic Pain

2,928 studies on the registry are indexed under Chronic Pain; 699 are open to participants now.

This study's enrollment of 92 is below the median of 126 across 687 observational studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

National Center for Complementary and Integrative Health (NCCIH) is the lead sponsor of 218 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • INCLUSION CRITERIA:

Inclusion Criteria for Patients:

  1. Patient must be greater than or equal to 18 years of age.
  2. Patient must be able to comprehend English.
  3. Patient must be able to provide written informed consent.
  4. Patient must have had chronic widespread pain for at least one year prior to participation with an average daily intensity at least 4 out of 10.

Inclusion Criteria for Healthy Controls:

  1. Healthy control must be greater than or equal to 18 years of age
  2. Healthy control must be able to comprehend English.
  3. Healthy control must be able to provide written informed consent.

EXCLUSION CRITERIA:

Exclusion criteria for patients:

  1. Patient is unable to comply with study procedures or follow-up visits
  2. Patient smokes more than 10 cigarettes of nicotine per week.
  3. Patient uses recreational drugs.
  4. Female patient consumes more than 7 half-pint beers, 7 6-oz glasses of wine or 7 1-oz shots of spirits (or equivalent) per week, and male patient consumes 14 such drinks per week. Further, patient consumes more than 5 drinks at one time.
  5. Patient is pregnant or breastfeeding.
  6. Patient has a major medical condition, such as kidney, liver, cardiovascular, neurological or current psychiatric condition.
  7. Patient has currently or has had in the past major depression, bipolar disorder, psychosis or suicide attempts.
  8. Patient has metal in his/her body which would make having an MRI scan unsafe, such as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have.
  9. Patient is uncomfortable in small closed spaces (has claustrophobia) so that he/she would feel uncomfortable in the MRI machine.
  10. Patient cannot lie comfortably flat on his/her back for up to 75 minutes in the MRI scanner.
  11. Patient has allergies to topical treatment.
  12. Patient has a chronic pain condition other than FM.
  13. Patient has taken within the last two weeks opioids. Other medications used to treat fibromyalgia at the standard doses in the community can be taken. We will not ask participants to stop any medication to participate in the study.
  14. Patient has previously taken opioids for more than one month on a continual basis, within the last 6 months.
  15. Patient had seen study information on clinicaltrials.gov prior to September 23, 2013.
  16. Patients who decline to be audio and/or videotaped will be excluded from the qualitative interview component of the study.

Exclusion criteria for healthy controls:

  1. Healthy control is unable to comply with study procedures or follow-up visits
  2. Healthy control smokes more than 10 cigarettes of nicotine per week.
  3. Healthy control uses recreational drugs.
  4. Female healthy control consumes more than 7 half-pint beers, 7 6-oz glasses of wine or 7 1-oz shots of spirits (or equivalent) per week, and male healthy control consumes 14 such drinks per week. Further, healthy control consumes more than 5 drinks at one time.
  5. Healthy control is pregnant or breastfeeding.
  6. Healthy control has a major medical condition, such as kidney, liver, cardiovascular, neurological or current psychiatric condition.
  7. Healthy control has currently or has had in the past major depression, bipolar disorder, psychosis or suicide attempts.
  8. Healthy control has metal in his/her body which would make having an MRI scan unsafe, such as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments,
05

Study design

Time perspective
Prospective
Enrollment
92 participants (actual)
06

What researchers measure

Primary outcomes

  1. Pain Perception

    Time frame: 3 years

07

Study locations

1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
08

References and documents

Publications

  • Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, Gitelman DR. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004 Nov 17;24(46):10410-5. doi: 10.1523/JNEUROSCI.2541-04.2004. PubMed 15548656 ↗
  • Atlas LY, Bolger N, Lindquist MA, Wager TD. Brain mediators of predictive cue effects on perceived pain. J Neurosci. 2010 Sep 29;30(39):12964-77. doi: 10.1523/JNEUROSCI.0057-10.2010. PubMed 20881115 ↗
  • Baliki MN, Geha PY, Fields HL, Apkarian AV. Predicting value of pain and analgesia: nucleus accumbens response to noxious stimuli changes in the presence of chronic pain. Neuron. 2010 Apr 15;66(1):149-60. doi: 10.1016/j.neuron.2010.03.002. PubMed 20399736 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01878019
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
Responsible party
Sponsor
First posted
Jun 14, 2013
Start date
May 28, 2013
Primary completion
Sep 8, 2016
Completion
Sep 8, 2016
Last update
Dec 9, 2019

Study contacts

Mary C Bushnell, Ph.D.
principal investigator · National Center for Complementary and Integrative Health (NCCIH)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion